Introduction
Neuroendocrine tumours (NETs) can develop in most organs. 1 NETs are usually slow growing tumours with behaviour ranging from relatively benign to highly malignant. [2] [3] [4] Due to their heterogeneous embryological origin, NETs are ubiquitous and because of their rarity can be difficult to distinguish by biologic and histopathologic features. [5] [6] [7] NETs are widely regarded as a rare tumour, with an incidence of 1-5 cases per 100,000 person-years. 3, 8, 9 The low incidence rate has resulted in only a few relevant studies, and makes a large experience for any single healthcare professional unlikely. [10] [11] [12] A high quality database with reliable diagnoses, which needs large clinical experience, is a condition sine qua non for epidemiological research on any rare disease. 13 A major step forward in predicting the biological behaviour of NETs was made in 2000 by the development of a new World Health Organization (WHO) morphological classification, including NETs, based on histopathological and biological characteristics. 6, 10, 14 Later, a Tumour-Node and Metastases (TNM) classification and the European Neuroendocrine Tumour Society (ENETS) grading system for NETs became available. 10, 15 Multiple systems of nomenclature, grading and staging have been proposed, however, none has achieved universal acceptance. In general, the current WHO guidelines divide neuroendocrine neoplasms into two clinically distinct pathologic classes: well-and poorly differentiated.
The well-differentiated NETs can be classified as either grade 1 or grade 2 depending on proliferation A comprehensive analysis of NETs in Europe is lacking within the available literature. This paper delineates the burden of NETs in Europe, providing estimates of the incidence, prevalence and survival of these tumours diagnosed from 1988 to 2002, based on the definition and list provided by the project surveillance of rare cancers in Europe (RARECARE). Although the recent improvements regarding pathologic diagnosis and grading of NET are a major step forward, the RARECARE list, and therefore our analysis, are based on the nomenclature during the time of our study period 1995-2002.
Materials and methods

Tumour grouping
The present analyses are based on the list of cancers provided by the RARECARE project. RARECARE included data between 1978 and 2002 and followed the 2000 WHO guidelines that distinguished NETs in four main groups: well differentiated endocrine tumours; well differentiated endocrine carcinoma; poorly differentiated endocrine carcinoma and mixed endocrine-exocrine carcinoma.
The RARECARE list of NETs is organised in two hierarchical tiers and based on the International Classification of Diseases for Oncology third edition (ICD-O3). 16 Tier 1 consists of cancers that require the same clinical expertise and patient referral structure, created by grouping tier 2 entities. Tier 2 includes cancers that are similar from the point of view of clinical management and research, and is based on the combination of topographical and morphological ICD-O3 codes.
For NETs described in this paper (Table 1) , there is one tier 1: 'neuroendocrine tumours' and eight tiers 2 (including: well differentiated endocrine tumours [identified in the ICD-O3 as carcinoids]; well differentiated endocrine carcinoma [identified in the ICD-O3 as atypical carcinoids]; well differentiated endocrine carcinomas of the pancreas and digestive organs [non-functioning]; well differentiated endocrine carcinomas of the pancreas and digestive tract [functioning]; poorly differentiated endocrine carcinomas [skin and thyroid excluded]; mixed endocrine-exocrine carcinomas; endocrine carcinomas of thyroid gland and endocrine carcinomas of the skin). Table 1 presents the ICD-O3 morphology and topography codes of NETs considered in the present study.
The RARECARE list grouped NETs from all anatomic sites. In this study well differentiated endocrine carcinomas of the pancreas and digestive organs are divided according to WHO grouping into functioning and non-functioning endocrine carcinomas. Well differentiated endocrine carcinomas (functioning) produce hormones and other local mediators and are associated with syndromes related to this hormone over secretion. Well differentiated endocrine carcinomas (non-functioning) exhibit immuno-positivity for endocrine markers but are not related to any hyperfunctional clinical syndrome. 17 This differentiation results in grouping them separately from well differentiated endocrine tumours and well differentiated endocrine carcinomas of other sites.
We included two separate tiers for thyroid and skin NETs: endocrine carcinoma of the thyroid gland and endocrine carcinoma of the skin. Including these two specific tiers results in the exclusion of skin and thyroid from poorly differentiated endocrine carcinomas, and from well differentiated endocrine tumours and well differentiated endocrine carcinomas.
The morphology codes for thyroid endocrine carcinomas include medullary carcinomas, poorly differentiated thyroid endocrine tumours and mixed medullary-follicular carcinoma. Endocrine carcinomas of the skin include Merkel cell carcinoma. Finally, poorly differentiated endocrine carcinomas include small cell endocrine carcinoma and large cell endocrine carcinoma of all sites except skin and thyroid. NETs of the lung will not be described in this article as their European incidence rate was 7.3 per 100.000 person-years, and therefore not considered to be rare. 18 
CRs selection and population coverage
RARECARE gathered data on cancer patients diagnosed from 1978 to 2002, registered in 89 populationbased CRs, all of which had information on follow-up available up to at least 31st December 2003. However this paper considered data from 76 CRs, excluding CRs which did not classify cancers according to the ICD-O3, and also those which collected data on childhood cancers only.
Data selection for incidence analysis
The incidence analysis considered incident cases between 1995 and 2002. We excluded twelve specialised CRs, as those registered data on specific cancer sites only. As a result, the incidence analyses were restricted to 64 CRs. Incidence rates were estimated as the number of new cases occurring between 1995 and 2002 divided by the total person-years in the general population (male and female) in the CR areas considered, over the same period. For age-standardised rates, the European standard population was used. 19 For estimating the number of cases that arises per year in all 27 European member states (EU27), the observed RARECARE incidence rates 1995-2002 were multiplied to the total 2008 EU27 population (497,455,033 at 2nd April 2008) provided by EURO-STAT. In providing NET burden estimates, we assumed that the population covered by the CRs included was representative of the population of the EU27 as a whole.
Data selection for prevalence analyses
The observed prevalence of cases within 2, 5 and 15 years before the index date of 1st January 2003 was estimated by applying the counting method. 20 Only 22 CRs had incidence and follow-up data available for the 15 The completeness index method 21 was used to estimate the EU complete prevalence, which involved adding the estimated surviving cases diagnosed prior to 1988 to those observed in 1988-2002. The completeness index was obtained on the basis of a parametric approach, by modelling 1985-1999 incidence data with a logistic exponential or polynomial function on age, and 1988-1999 survival with mixture cure models. 22 The expected number of prevalent cases in EU27 was estimated by multiplying the prevalence estimates to the 2008 European population (497,455,033 at 2nd April 2008 provided by EUROSTAT).
Data selection for survival analyses
Period survival indicators for the years 2000-2002 were estimated using the Brenner algorithm. 23 Period analysis provides more up-to-date survival experience by considering survival experience in 2000-2002. Forty-six CRs out of the 76 European CRs had data available for this period, and could be included for survival analyses.
Data quality analysis
International standards for CRs set by the International Association for Cancer Registries (IACR) and the European Network of Cancer Registries (ENCR) attempt to secure the quality of the CRs, but consideration must be given to constraints on their activity placed by local health care systems. 24 In summary, during the registration process there was access to comprehensive sources including pathologic reports, diagnostic examinations and clinical dossiers. Especially for NETs, it is important to have access to, and use of all sources provided by multidisciplinary teams (including experienced pathologists) to come to a correct definition of NETs.
The main data quality indicators for the 21,066 NETs are shown in Table 1 . These cases were diagnosed between 1995 and 2002 and archived by the 76 CRs considered in the study. Overall, 0.34% of the cases were Death Certificate Only (DCO), ranging from 0.00% for well differentiated endocrine tumours (atypical carcinoid) (N = 6 in four CRs) and endocrine carcinomas of thyroid gland (N = 1784 in 64 CRs) to 5.6% for the mixed endocrine-exocrine carcinomas of the pancreas (N = 18 in 16 CRs).
Nearly 97% of all NETs included in the RARECARE database were histologically verified (MV), however the proportion of MV cases ranged from 100% for the six cases of well differentiated endocrine tumours (atypical carcinoid) to 85% for the well differentiated endocrine carcinoma (functioning of pancreas and of digestive tract).
The proportion of cases diagnosed between 1995-1998 and censored before 5 years of follow-up (lost to follow-up) was 1.2%, ranging from 0.00% for the well differentiated endocrine tumours to 2.5% for the well differentiated endocrine carcinomas (functioning pancreas and digestive tract).
EU regions
Differences among European regions have been established by grouping the RARECARE participating cancer registries by country and grouping the countries into 5 main European regions following the European cancer registry-based study on survival and care of cancer patients (EUROCARE) study: 25 Northern Europe (Iceland, Norway, Sweden), United Kingdom and Ireland (England, Scotland, Wales, Northern Ireland, Republic of Ireland), Central Europe (Belgium, Austria, France, Germany, the Netherlands, Switzerland), Eastern Europe (Poland, Slovakia), and Southern Europe (Italy, Malta, Portugal, Slovenia, Spain). For 11 countries, CRs covered the entire national population (Austria, Iceland, Ireland, Malta, Norway, Slovakia, Slovenia, Sweden, Northern Ireland, Scotland, Wales and England). The other 10 countries were represented by regional CRs, covering variable proportions of their respective national populations.
Results
Incidence
The incidence rate is presented per 1,000,000 personyears in Europe (crude rate) in Table 2 . Table 2 shows also rates by sex (age adjusted rate), age group and the estimated number of new cases expected in EU27 every year. Well differentiated endocrine carcinomas of Statistic could not be calculated. NOS: not otherwise specified. the pancreas and digestive organs (non-functioning) were the most common tumours among NETs, with a crude incidence rate of 13 per 1,000,000 person-years, followed by poorly differentiated endocrine carcinomas (skin and thyroid excluded), with a crude rate of 5.2 per 1,000,000 person-years. For all other entities the crude incidence rate was below 4.0 per 1,000,000 person-years ( Table 2 ). The localisation of NETs was 65% at 8 different sites: small intestine (18%), thyroid gland (8.6%), pancreas (8.0%), colon (7.0%), stomach (6.9%), appendix (5.5%), rectum (5.3%) skin (5.0%). The other 35% were located at sites such as female and male genital organs, head and neck and other sites. Within these 35% we found that there was no specific site registered for 19% of all NETs, which accounted for 60% of the column included 'others' (Table 3) .
NETs were more common in men, except for endocrine carcinoma of the thyroid gland. The incidence rate was highest in patients aged 65 years and older, ranging from <0.10 up to 40 per 1,000,000 person-years. We estimated 12,600 new cases per year for EU27, of which 6250 (50%) were well differentiated endocrine carcinomas of the pancreas and digestive organs (non-functioning) ( Table 2) . Table 4 shows the age standardised incidence rate by European region between 1995 and 2002. There was a geographical variation in age standardised incidence, with the highest rates in Northern Europe (32 per 1,000,000) and the lowest in Eastern Europe (7.5 per 1,000,000) ( Table 4) . Table 5 shows the estimated complete prevalence in Europe and the observed prevalence proportion of those diagnosed 2, 5 and 15-years before the index date (1st January 2003). Over 100,000 people (last column of Table 5 ) were estimated to be alive in EU at the beginning of 2008 with a diagnosis of NET.
Prevalence
Of these, 20% (20,262 over 100,003) and 40% (39,717 over 100,003) were diagnosed within 2 and 5 years before the index date, respectively. The difference (20%) between these two proportions represents the proportion of cases diagnosed 3-4 years before the index date, and therefore presumably still undergoing clinical follow-up. The remaining 60% represents those surviving over 5 years after diagnosis, 34,200 of those (34% of the total) surviving more than 15 years after their initial diagnosis.
Well differentiated endocrine carcinomas of the pancreas and digestive organs (non-functioning) were estimated for the year 2008 to be the most prevalent endocrine tumours (63,700 cases), followed by endocrine carcinomas of thyroid gland (16, 200 cases) , well differentiated endocrine carcinoid tumours (7800 cases), and poorly differentiated endocrine carcinomas (skin and thyroid excluded) (6700 cases). The remaining second tier entities of NETs accounted for less than 6000 prevalent cases.
The distribution of prevalent cases by time since diagnosis varied between the different tumour entities depending on the prognosis of the specific tumour type and the mean age of incidence (Table 5) .
Endocrine carcinomas of the thyroid gland had the highest proportions of very long term survivors who survived over 15 years following diagnosis (44%). Around 70% of endocrine carcinoma of the thyroid gland occurred in the age groups under 65 years of age. differentiated endocrine carcinomas of the pancreas and digestive organs (non-functioning) had the second best 5-year relative survival with a rate of 64% (N = 3540). Well differentiated endocrine tumours, and poorly differentiated endocrine carcinomas (skin and thyroid excluded) had the poorest 5-year relative survival: 30% (N = 1144) and 12% (N = 1543) respectively (N not in tables). The 5 year relative survival for mixed endocrine-exocrine carcinomas was 62% but based on only seven cases. The number of cases (N = 6) was too little to calculate the 5-year relative survival with the period survival method 23 for well differentiated endocrine tumours atypical carcinoid. Fig. 2 shows that NETs of appendix and thyroid gland had the highest survival, followed by NETs diagnosed in the rectum and the small intestine. NETs of the pancreas and the Head and Neck had the poorest survival with a 5-year relative survival rate of 41% (N = 564) and 31% (N = 54). Survival was consistently lower for patients of 65 years or over than for younger patients (data not shown).
Survival
Discussion
The availability of a high quality European database has given us the opportunity to obtain a large scale European study on NETs. This study gives a unique possibility to compare our large scale EU data on NETs with already existing small cohort studies, reviews, case reports and large cohort studies from other countries and continents. 8, 26, 27 The major indicators of data quality (Table 1) indicate a high quality dataset with 97% of cases histologically confirmed. However, the main concern when studying such rare tumours, relates to the accuracy of diagnosis and the completeness of registration. The recent improvements regarding pathologic diagnosis and grading of NETs are a major step forward, however we had to use the nomenclature at the time of our study period 1995-2002, and we had to rely on the diagnosis reported in the clinical records.
The RARECARE group assessed the quality of data and the extent of registration bias undertaking a dedicated study in collaboration with CRs providing the data. RARECARE reviewed the original data of a selected sample (N = 3000) focusing on undifferentiated (ICD-O3 code 8020/3) and anaplastic (ICD-O3 code 8021/3) carcinomas of the digestive tract (ICD-O3 code C15 to C25). 28 The objective of this review was to identify additional cases, if any. This check led to only 10 additional cases out of 929 cases of undifferentiated and anaplastic carcinomas identified. Also, all carcinoids (ICD-O3 codes 8240-8244) of the digestive tract were reviewed to assess their behaviour. Pathological reports were reviewed looking for information on depth of invasion, tumour size and Ki67 labelling index. Unfortunately, most prognostic information regarding so called carcinoids of the digestive tract were missing in the majority of pathological reports. This finding suggests that the quality of diagnosis was high, although major concerns can be raised regarding the completeness of prognostic parameter evaluation. Our data clearly indicate that the referral of NETs to an expert pathologist would greatly impact on diagnostic accuracy, as well as on evaluation of prognosis across the EU. Where ENETS is giving practical guidelines for diagnosis and treatment of NETs, no information is available on the criteria for expert pathologists.
Our data confirm results presented by other small sets of population based studies that report an incidence rate for NETs (NETs of the lung excluded) of around 2 per 100,000 person-years. 3, 8, 9 The overall survival rate shown is broadly in line with the literature 27 , which seems to relate to anatomic sites, i.e. 86% in the appendix, 71% in the small intestine, and 41% in the pancreas ( Fig. 2) . A population based study included potential prognostic parameters in their study model including disease stage, primary tumour site, histology, age, sex, race and period of diagnosis, and found all parameters to be significant. 27 Regarding well differentiated endocrine tumours, our analysis describes four different subgroups of neuroendocrine tumours: (1) well differentiated endocrine tumours, (2) well differentiated endocrine carcinoma, (3) endocrine carcinoma of the pancreas and digestive organs (non-functioning) and (4) the endocrine carcinoma of the pancreas and digestive tract (functioning) ( Table 1) .
Well differentiated endocrine tumours are less aggressive than poorly differentiated endocrine tumours, indicated by their lower Ki67 index. 29 The age standardised incidence rates within the well differentiated endocrine tumours showed a difference between the different EU regions (Table 5 ). The difference for the well differentiated endocrine carcinoma of the pancreas and digestive tract (non-functioning) was most marked. The highest age adjusted rate was found in the Northern Europe and the lowest rate was found for the Eastern Europe region. Unfortunately, we could not find studies confirming this result. For both regions the percentage of histologically verified cases was similar. The difficulties in reaching a diagnosis (by non-expert pathologists or limited diagnostic mean available), the availability of organised NET centres, the use of endoscopic surveillance or the existence of national hereditary screening programs could all contribute to explain the observed difference in incidence. Differences in incidence could also be due to different distribution of risk factors in the population, however, limited information is available on NET risk factors. An important limitation of this study is that the Eastern region is represented by only four CRs, in contrast to the Northern EU region, represented by National CRs including the whole population of those countries.
Our data are consistent with the literature for the majority of well differentiated endocrine tumours. 30 The literature for carcinoids shows a wide variation in survival rates, related to the different sites in which carcinoids have been found. 31 In our study, the survival for well differentiated endocrine tumours of the digestive tract was 52% for the functioning tumours and 64% for non-functioning, respectively. For the other sites, 5 year relative survival was of 30% (Fig. 1) . This low survival can be explained by two facts. Most carcinoids are diagnosed having already metastasised, 30 resulting in limited possibilities for potentially curative treatment. 31 For example, surgery is considered an effective treatment in early stage NETs, but once metastasised there are limited options for potentially curative treatment. Single agent chemotherapy, results in very low response rates of about 10%. 31 Secondly, the majority of the carcinoids with poor prognosis are those of unknown primary site (ICD-O3 code C80.9).
Results on incidence, prevalence and survival for the endocrine atypical carcinoid tumours should be interpreted with caution as they were based on a very limited number of cases (N = 6 in three differentiated sites). However, this is the first time these outcomes are reported.
The poorly differentiated endocrine carcinomas are characterised by a high grade of malignancy and poor prognosis. 32 Our study reported a 5-year relative survival of 12%. As the expected number of incident cases covers over 20% of all expected cases of NETs in EU27 this observation seriously affects the overall 5 year relative survival of NETs. We found a predominance in men (1:0.6) and a peak incidence in people older than 65 years. This male predominance was also found by other studies. 33, 34 Endocrine carcinoma of the thyroid, mainly including medullary carcinomas with amyloid stroma, represented just over 8.5% of the total number of NETs. A female predominance and an increase in age standardised incidence rate through age was found, confirming results seen elsewhere in the literature. 35, 36 A pooled analysis of 14 different case control studies in different continents found a relationship between having a first child after the age of 25 years and a significantly increased risk for developing medullary thyroid cancer. 36 This could partly explain the rise in incidence for the female gender through age.
The survival analyses showed better survival following diagnosis at a younger age (ranging from 100% for the age group 0-14 to 70% for the age group >65). This higher survival in age 0-14 might be affected by standardised surveillance programmes, which allows the early detection of micro carcinomas and the possibilities for a complete cure. 37 These cases of early detection are included in our analyses. The literature reports 25% of all medullary thyroid carcinomas being familial. 38, 39 These results found are in line with a population based study which included the SEER population for the period 1973-1991. 35 The 5 year relative survival of the endocrine carcinoma of the thyroid gland (82%) was by far the best seen within NETs (Fig. 1) . It is well known that surgery after early detection of thyroid medullary carcinomas offers a near 100% cure rate. 40 Mixed endocrine-exocrine carcinomas are rare pancreatic neoplasms and most arise as a single type cell, either from the endocrine or exocrine pancreas. To make an accurate diagnosis of these tumours is difficult, because a lesion is only categorised to be a mixed endocrine-exocrine carcinoma when the endocrine cells exceed 25-30% of the tumour 41 and complete resection of the tumour is needed for the final diagnosis. We only identified 18 cases of mixed endocrine-exocrine carcinoma, so no conclusions can be drawn. However, for the mixed endocrine-exocrine carcinomas 89% of the cases included were microscopically verified. We found similar results on survival compared to the study done by Yao et al., 27 who report a median survival of 135 months. Both, Yao et al. and our study found that mixed forms have a survival similar to well differentiated carcinoid tumours. 27 Endocrine carcinoma of the skin mainly includes the Merkel cell carcinoma which has an aggressive behaviour. 42 We found an annual incidence rate of 1.3/ 1,000,000, resulting in an estimated number of 600 Merkel cell carcinomas each year in the EU27, with a highest incidence in the age category 65+. The 5 year relative survival of 58% was consistent with the 59% reported in previous studies. [43] [44] [45] [46] The Finnish cancer registry found a small predominance in female and a mean age of 76 years at time of diagnosis. 45 This small discrepancy in relation to our study might be caused by the fact that the Finnish cancer registry only included 181 cases of Merkel cell carcinomas, while we observed 1079 Merkel cell carcinomas within our study.
Classifying NETs is an on-going debate. 47 In 2010 the WHO has presented a new classification of NETs in the digestive tract, 48 , while the classification for NETs of the lung has already existed since 1994. 49 The evolution of the classification of NETs is still incomplete, for example different anatomic site (such as lung) still use different terminologies. This paper, far from trying to resolve such issues, may contribute to improve data quality on this important subset of cancers. We would encourage this debate by publishing population based data collected by CRs all over Europe, showing results based on a relatively large number of cases for a relatively rare tumour.
From the quality check conducted by the RARE-CARE study we can conclude that despite 97% of the cases being histologically confirmed, the completeness of case ascertainment of NETs is still not always being achieved. 50 It is extremely important that in future classification nomenclatures become homogenous for all anatomic sites. In addition strong educational efforts should be made in order to familiarise with punctual registration of key prognostic factors such as mitotic count as well as ki67 labelling index.
In contrast to previous studies, usually based on small numbers of cases, our study is based on a large series of patients. Because of the complexity and lack of knowledge of the different disciplines involved in the management of NETs, a multidisciplinary approach on NETs is desirable. 51 To support this multidisciplinary approach, highly qualified reference centres, guidelines and an international network between those centres is recommended.
